30 January 2026
PPTA and the EPA warmly welcome Hungary’s initiative to launch its Donor Registry, which was implemented recently, in early 2026. This marks a significant advancement in ensuring donor health and safety by enhancing tracking and enforcing donation frequency and also supports the continuous and safe supply of lifesaving medicines made from plasma.
As our organisations have previously communicated, EPA and PPTA fully endorse the Donor Registry developed by the Hungarian National Blood and Transfusion Service (OVSZ). We stand by this commitment and emphasise that its development and entry into service is crucial for the plasma industry in Europe, both in improving donor safety and in ensuring compliant donation frequency. The registry, as noted by Hungary’s local plasmapheresis association (Védettség),“provides a uniform and transparent registry that protects the health of plasma donors by monitoring the frequency of donations, provides data protection guarantees and strengthens trust in a safe, regulated process."
It is also a crucial effort towards Europe’s desire to become more self-sufficient in its plasma supply. Patients who rely on plasma-derived medicines often have rare and chronic conditions for which there are no alternative treatments, making the need for regular plasma donation critical. Additionally, there is a growing global need for immunoglobulins, and a healthy and committed donor pool is necessary to meet this clinical need.
The plasma industry deeply values the commitment of plasma donors. Without their generosity, producing lifesaving plasma-derived medicinal products across Europe would simply not be possible. The safety and well-being of these dedicated individuals remain paramount, and this registry represents a crucial measure to uphold that commitment.
PPTA and the EPA remain committed to cooperating with the National Blood Service (OVSZ), patient organizations and government actors in order to ensure the safety and supply of plasma-based medicines in Hungary.